

 **CONFIDENTIAL**

|  |  |
| --- | --- |
| ***Quebec/Germany 2015 Joint Program******Short Common Form******DEADLINE: 15th September*** | For internal use |
| File # : [Keywords] |
|   |
|

**This form must be filled in with “Arial 11” font, typed at 1.15 line spacing.**

|  |  |
| --- | --- |
| ***Total Amount of the Project*** |  |
| **Amount Requested from CDQM** | [Amount] |
| **Amount Requested from Germany**  |  |
| **TITLE OF THE PROJECT (In English)** |
| [Title] |
| **IDENTIFICATION OF THE PRINCIPAL INVESTIGATOR (PI)**  |
| *Last name:* |  | *First name:* |  |
| *Private Organization or University/Department:* |  |
| *Address:* |  |
| *City:* |  | *Province:* |  | *Postal code:* |  |
| *Country:* |  | *Phone #:* |  | *Ext:* |  |
| *Email:* |  |
| **IDENTIFICATION OF THE PRINCIPAL INVESTIGATOR (PI) (Germany)** |
| *Last name:* |  | *First name:* |  |
| *Private Organization or University/Department:* |  |
| *Address:* |  |
| *City:* |  | *Province:* |  | *Postal code:* |  |
| *Country:* |  | *Phone #:* |  | *Ext:* |  |
| *Email:* |  |

|  |
| --- |
| **IDENTIFICATION OF THE RESEARCH GROUP (PI AND THE CO-INVESTIGATORS) (including those from private organizations). *Add lines if necessary*** |
|  | **Name** | **Affiliation** | **Email address** | **Expertise**  | **Work package title and number** |
| **1****PI** |  |  |  |  |  |
| **2****PI** |  |  |  |  |  |
| **3** |  |  |  |  |  |
| **4** |  |  |  |  |  |
| **5** |  |  |  |  |  |
| **6** |  |  |  |  |  |
| **7** |  |  |  |  |  |
| **8** |  |  |  |  |  |

|  |
| --- |
| **SECTION 1. PROJECT SUMMARY (max. 1000 characters)** |
| Define the following aspects of your project: background information, current state of the technology, objectives and brief research plan, referring to each partner’s specific work package (defined in more details in section 4).  |

|  |
| --- |
| **SECTION 2. Short description of expertise / business sector (max. 500 characters)** |
|  |

|  |
| --- |
| **SECTION 3. PROJECT DELIVRABLES (max. 500 characters)** |
| The deliverables are the concrete, tangible work products resulting from the completion of the project.Use bullet points and define the tangible assets that will result from your work Briefly explain how and in what form the deliverables may be transferable to the industry and its intended use in the drug R&D process  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **SECTION 4. IMPACT ON DRUG R&D (750 characters)**Select which main step(s) of the drug discovery and/or development process your project is most likely to impact:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Target identification | Discovery / screening | Lead optimization | Preclinical studies | Clinical development |

 |
| Describe how the technology is aligned with pharma needs and how it will improve, enhance or accelerate the drug discovery and R&D process*.*If applicable, describe the impacts on: * Opening new therapeutic approaches and research avenues
* Bringing more effective medicines to the clinic and to the market
* Increasing the efficacy of existing drugs
* Reducing R&D costs, time to market or decreasing the risks of development and attrition rate
* Other impacts on the drug discovery and development process
 |

|  |
| --- |
| **SECTION 5. WORK PACKAGES and TEAM COLLABORATION**  |
| 1) Discuss the role of both PIs in the achievement of the research in relations to other work packages (max. 500 characters).2) Number and describe briefly each of the partner’s work packages / contributions to the project (max. 250 characters for each work package). Please add start date and duration of each work plan. 3) Discuss the synergies and complementarities of the team (max. 500 characters).  |

|  |
| --- |
| **Estimated timeline and costs in Can$ and €** |
|  | **Name** | **Work package title and number** | **Timeline** | **Cost in €** | **Cost in Can$**  |
| **1****PI** |  |  |  |  |  |
| **2****PI** |  |  |  |  |  |
| **3** |  |  |  |  |  |
| **4** |  |  |  |  |  |
| **5** |  |  |  |  |  |
| **6** |  |  |  |  |  |
| **7** |  |  |  |  |  |
| **8** |  |  |  |  |  |

|  |
| --- |
| **SECTION 6. PRINCIPAL INVESTIGATOR’S SIGNATURES** |
| 1. I authorize CQDM to exchange all information in relation to my file for evaluation purposes, under the condition that the confidential character is respected by the individuals who are given access to this information.
2. I obtained the agreement from all the co-investigators to participate in this research project.
3. I certify that all information provided in this application is complete and accurate to the best of my knowledge.
 |
|  |
|  |  |  |  | *Signature (Quebec) :* |  |  |
|  |  |  |  | *Date :* |  |  |
|   |  |  |  | *Name :*  |  |  |
|  |  |  |  | *Signature**(Germany) :* |  |  |
|  |  |  |  | *Date :* |  |  |
|  |  |  |  | *Name :* |  |  |
|   |  |  |  | *Name :*  |